Mark Avagliano

2022

In 2022, Mark Avagliano earned a total compensation of $1.1M as Chief Business Officer at G1 Therapeutics, a 25% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$154,382
Option Awards$380,207
Salary$465,005
Stock Awards$128,280
Other$9,150
Total$1,137,024

Avagliano received $465K in salary, accounting for 41% of the total pay in 2022.

Avagliano also received $154.4K in non-equity incentive plan, $380.2K in option awards, $128.3K in stock awards and $9.2K in other compensation.

Rankings

In 2022, Mark Avagliano's compensation ranked 2,780th out of 5,701 executives tracked by ExecPay. In other words, Avagliano earned more than 51.2% of executives.

ClassificationRankingPercentile
All
2,780
out of 5,701
51st
Division
Manufacturing
1,544
out of 3,099
50th
Major group
Chemicals And Allied Products
715
out of 1,406
49th
Industry group
Drugs
667
out of 1,307
49th
Industry
Pharmaceutical Preparations
481
out of 953
50th

Pay ratio

Mark Avagliano's Pay$1,137,024
Median Employee's Pay$243,930
Pay Ratio

5

to 1

In 2022, the annual total compensation of Mark Avagliano was $1,137,024.

The annual total compensation of the median employee at G1 Therapeutics was $243,930.

The ratio of Mark Avagliano's pay to the pay of median employee was therefore 5 to one.

Source: SEC filing on April 26, 2023.

Avagliano's colleagues

We found two more compensation records of executives who worked with Mark Avagliano at G1 Therapeutics in 2022.

2022

John Bailey

G1 Therapeutics

Chief Executive Officer

2022

Jennifer Moses

G1 Therapeutics

Chief Financial Officer

News

You may also like